Standout Papers

Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials 2020 2026 2022 2024425
  1. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials (2020)
    Philippe Gevaert, Theodore A. Omachi et al. Journal of Allergy and Clinical Immunology

Immediate Impact

2 from Science/Nature 34 standout
Sub-graph 1 of 12

Citing Papers

Macrophages in cardiovascular diseases: molecular mechanisms and therapeutic targets
2024 Standout
Refining the impact of genetic evidence on clinical success
2024 StandoutNature
2 intermediate papers

Works of Monet Howard being referenced

Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials
2020 Standout
Phase 2 trial to assess lebrikizumab in patients with idiopathic pulmonary fibrosis
2020

Author Peers

Author Last Decade Papers Cites
Monet Howard 212 355 330 394 10 781
Kathryn L. Pothoven 21 124 140 123 12 888
M Honma 32 29 514 158 13 805
Kirsty Mallett 22 26 634 339 8 890
Yan Song 4 84 488 141 12 863
Kit Wong 3 364 418 450 9 673
Meghan Cundall 13 19 432 120 11 665
Saara Kantola 19 343 20 31 13 799
Dean Toy 90 11 200 57 6 960
Patrick J. Oliverio 154 83 45 9 15 873
Wouter Bauters 1 458 391 402 22 802

All Works

Loading papers...

Rankless by CCL
2026